STOCK TITAN

Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will speak at the Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET. The presentation will be available via webcast on the company's Investors page and archived for later viewing. Merus specializes in developing full-length multispecific antibodies, known as Biclonics® and Triclonics®, with potential applications in oncology.

Loading...
Loading translation...
Argus Session date unavailable
-1.52% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was -1.52%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:50 p.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and Twitter.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event will Merus N.V. participate in on November 16, 2022?

Merus N.V. will participate in the Stifel 2022 Healthcare Conference on November 16, 2022.

Who will represent Merus N.V. at the Stifel conference?

Bill Lundberg, M.D., the CEO of Merus N.V., will represent the company at the conference.

What time is Merus N.V.'s presentation at the Stifel Healthcare Conference?

The presentation by Merus N.V. is scheduled for 1:50 p.m. ET on November 16, 2022.

How can I access the Merus N.V. presentation from the Stifel conference?

The presentation will be available via webcast on the Investors page of Merus N.V.’s website.

What type of products does Merus N.V. develop?

Merus N.V. develops innovative full-length multispecific antibodies, known as Biclonics® and Triclonics®, for oncology.

Keep reading